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Abstract
Autophagy is the principal catabolic response to nutrient starvation and is necessary to clear 
dysfunctional or damaged organelles, but excessive autophagy can be cytotoxic or cytostatic and 
contributes to cell death. Depending on the abundance of enzymes involved in molecule 
biosynthesis, cells can be dependent on uptake of exogenous nutrients to provide these molecules. 
Argininosuccinate synthetase 1 (ASS1) is a key enzyme in arginine biosynthesis, and its 
abundance is reduced in many solid tumors, making them sensitive to external arginine depletion. 
We demonstrated that prolonged arginine starvation by exposure to ADI-PEG20 (pegylated 
arginine deiminase) induced autophagy-dependent death of ASS1-deficient breast cancer cells, 
because these cells are arginine auxotrophs (dependent on uptake of extracellular arginine). 
Indeed, these breast cancer cells died in culture when exposed to ADI-PEG20 or cultured in the 
absence of arginine. Arginine starvation induced mitochondrial oxidative stress, which impaired 
mitochondrial bioenergetics and integrity. Furthermore, arginine starvation killed breast cancer 
cells in vivo and in vitro only if they were autophagy-competent. Thus, a key mechanism 
underlying the lethality induced by prolonged arginine starvation was the cytotoxic autophagy that 
occurred in response to mitochondrial damage. Last, ASS1 was either low in abundance or absent 
in more than 60% of 149 random breast cancer bio-samples, suggesting that patients with such 
tumors could be candidates for arginine starvation therapy.
INTRODUCTION
Breast cancer is one of the most common cancers that kill women (1). Gene expression 
analyses of breast cancer have identified five intrinsic molecular “subtypes” (normal-like, 
luminal A, luminal B, basal, and HER2-positive), each of which has unique clinical and 
histological phenotypes (2, 3). Currently, breast cancers are subtyped so that different 
treatments can be tailored to maximize therapeutic benefit. However, it is still estimated that 
39,620 women and 410 men will die of breast cancer in the United States in 2013 to 2014 
(4). Therefore, it is necessary to identify new therapeutic targets, especially for treatment-
refractory tumors.
Altered cellular metabolism has emerged as a common phenotype of cancers and other 
complex diseases (5). Cancer cells adapt their metabolic pathways to meet the high-energy 
demands required for their accelerated growth and proliferation and the associated metabolic 
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stresses. Metabolomic studies have revealed that the steady-state abundance of many amino 
acids in stomach, colon, lung, and prostate cancers is higher than in the corresponding 
normal tissue, suggesting that the tumors have increased biosynthetic needs for amino acids 
(6, 7). For example, some tumor cells are addicted to glutamine because it supports anabolic 
processes and fuels proliferation (8, 9). The serine and glycine biosynthetic pathways have 
also been suggested to play critical roles in oncogenesis (10, 11). Here, we aimed to exploit 
the distinct metabolic requirements of breast cancers to identify impaired metabolic 
pathways that can be targeted for breast cancer treatment.
Among the metabolic adaptations that occur in cancer cells is the increased use of the amino 
acid arginine to fuel anabolic processes. Arginine is a nonessential amino acid in humans, 
but it plays a vital role in multiple metabolic pathways, including protein synthesis and the 
production of nitric oxide, polyamines, urea, creatine, nucleotides, proline, glutamate, and 
agmatine (12, 13). Arginine concentrations in cells are partly maintained by de novo 
synthesis from citrulline, which is converted to arginine by argininosuccinate synthetase 1 
(ASS1) and argininosuccinate lyase (ASL). Accumulating evidence suggests that the 
endogenous production of arginine is not sufficient to meet the needs of rapidly proliferating 
tumor cells (14-20). Thus, arginine is now considered a semiessential amino acid under 
stress conditions, and arginine auxotrophs are cells that have lost the ability to synthesize 
arginine and are dependent on external arginine sources. Paradoxically, although there is an 
increased demand for arginine by tumor cells, many human tumor cells, including 
melanoma, lymphoma, glioma, and prostate cancer, are ASS1-deficient and become arginine 
auxotrophs (http://www.proteinatlas.org/ENSG00000130707). The biological mechanisms 
underlying this paradox are not completely understood, and it may be that arginine 
auxotrophs have a previously overlooked metabolic liability that could be exploited to treat 
many cancers, including breast cancers. Thus, our analyses could not only improve our 
understanding of the biology of ASS1 deficiencies in cancer development and recurrence 
but also lead to the development of therapies that target arginine auxotrophic breast cancers.
Arginine deiminase (ADI) is a microbial enzyme originally isolated from mycoplasma that 
metabolizes arginine to citrulline and is 300-fold more effective than arginase at depleting 
arginine from the environment (21-23). Recombinant ADI has been used to deprive arginine 
auxotrophic tumors of external arginine, thereby inhibiting their growth. Sensitive tumors 
are usually ASS1-deficient and therefore incapable of synthesizing endogenous arginine (17, 
24-28). Conversely, overexpressing ASS1 in ASS1-deficient melanoma cells confers 
resistance to ADI (17, 29). Recombinant ADI-based therapies have been used in several 
clinical trials to treat advanced arginine auxotrophic melanoma and hepatocellular 
carcinoma, and have had acceptable response rates and minimal side effects (30-33). 
However, besides arginine depletion, the mechanism by which ADI mediates its effect is 
unknown. Recombinant pegylated ADI (ADI-PEG20) is a new form of ADI with increased 
safety and efficacy profiles. Nutrient starvation approach, including arginine depletion, will 
invariably induce autophagy in many cancer cells (34, 35); however, the biological 
relevance and consequence of autophagy induction in this context are not yet understood.
Here, we sought to identify the molecular determinants of sensitivity and resistance to 
arginine starvation therapy that could guide patient selection or the choice of agents to be 
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given in combination. We found that arginine starvation killed ASS1-deficient breast cancer 
cells by impairing mitochondrial energy production and increasing the generation of reactive 
oxygen species (ROS), which compromised mitochondrial integrity. The accumulation of 
impaired mitochondria would eventually result in autophagy-dependent cell death. We 
determined that ASS1-deficient breast cancer cell lines and mouse xenografts were 
susceptible to ADI-PEG20 only if they were autophagy-competent. In addition, more than 
60% of a random sample of 149 breast cancers had low abundance of ASS1 or no detectable 
ASS1, irrespective of the breast cancer molecular subtype. Thus, we defined the 
mechanisms that underlie the sensitivity of arginine auxotrophic breast cancer cells to 
arginine starvation and then analyzed the role of autophagy in this process.
RESULTS
ADI-PEG20 selectively inhibits the proliferation of ASS1-deficient breast cancer cells
We hypothesized that reduced ASS1 abundance would increase the sensitivity of breast 
cancer cells to arginine starvation by treatment with recombinant ADI-PEG20. We found 
that ASS1 mRNA and ASS1 protein abundance was relatively low in MDA-MB-231 and 
ZR-75-1 cells compared to MCF-7 and T47D cells (Fig. 1A). As predicted, the relative 
sensitivity of these four breast cancer cells lines to ADI-PEG20–induced inhibition of 
proliferation was inversely correlated with the abundance of ASS1 (MDA-MB-231 > 
ZR-75-1 > T47D ≈ MCF-7) (Fig. 1B). The inhibition of proliferation in MDA-MB-231 
cells by ADI-PEG20 was independently validated with a time course growth assay (fig. 
S1A) and by anchorage-independent colony formation assay (Fig. 1C). To confirm that the 
inhibition of proliferation by ADI-PEG20 was inversely related to ASS1 abundance, we 
established ASS1-overexpressing MDA-MB-231 (fig. S1B) and ASS1-knockdown T47D 
cells (fig. S1C). As predicted, MDA-MB-231 cells overexpressing ASS1 were more 
resistant to ADI-PEG20 (Fig. 1D), and the knockdown of ASS1 sensitized T47D cells to 
ADI-PEG20 (Fig. 1E). Together, our results indicate that recombinant ADI-PEG20 
effectively inhibits the proliferation of breast cancer cells with ASS1 knockdown, which 
cannot synthesize sufficient endogenous arginine for their metabolic needs. Unexpectedly, 
we noticed that although knockdown of ASS1 promoted ADI-PEG20 sensitivity (Fig. 1E), 
decreased ASS1 abundance increased the proliferation (fig. S1D) and the ability to form 
colonies (fig. S1E) in T47D cells. We speculated that ASS1 might play a tumor suppressor 
role in breast cancer cells. To test this possibility, we knocked down ASS1 in MCF-7 cells, 
which had the greatest ASS1 abundance of the five breast cancer cell lines (Fig. 1A) and 
exhibited resistance to ADI-PEG20 (Fig. 1, B and C). A 50% knockdown of ASS1 (fig. 
S1F) increased the anchorage-independent, colony-forming ability of MCF-7 cells, as well 
as their sensitivity to ADI-PEG20 when grown in soft agar (Fig. 1F). These data suggest that 
ASS1 may have a tumor suppressor function that prevents anchorage-independent breast 
cancer cell growth.
ADI-PEG20 induces autophagy-dependent cell death
Using MDA-MB-231 cells, we investigated the mechanism underlying arginine 
deprivation–induced cell death of breast cancer cells with low ASS1 abundance. We first 
determined if ADI-PEG20 induces apoptosis in MDA-MB-231 cells, as previously 
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suggested by studies using other cancer cells (28, 36). Flow cytometry indicated that about 
13% of MDA-MB-231 cells were annexin V–positive after being treated with ADI-PEG20 
or starved of arginine (Fig. 2A and fig. S2A). However, on the basis of the extent by which 
ADI-PEG20 inhibited cell proliferation (Fig. 1B), the apoptotic cell population was smaller 
than expected. It seemed likely that cell proliferation was inhibited by another pathway that 
was induced by ADI-PEG20.
Arginine starvation has been reported to induce autophagy (28, 37). We first determined 
whether ADI-PEG20 induced autophagy in MDA-MB-231 cells. During autophagy, a 
cytosolic form of microtubule-associated protein 1A/1B light chain 3 (LC3-I) is conjugated 
to phosphatidylethanolamine to form LC3-II, which inturn is recruited to autophagosomal 
membranes (38-41). Formation of GFP (green fluorescent protein)–LC3–positive puncta, a 
marker for autophagy (39), was monitored in MDA-MB-231 cells stably transfected with 
GFP-LC3 and treated with ADI-PEG20. GFP-LC3 puncta were observed 12 hours after 
ADI-PEG20 treatment, but were decreased after 24 hours, indicating the appearance and 
disappearance of autophagosomes (Fig. 2B). Next, we used Western blotting to show that 
LC3 was lipidated (LC3-II) and that LC3-II abundance increased to about twofold at 6 hours 
after ADI-PEG20 treatment, and then decreased over time (Fig. 2C). Furthermore, 
bafilomycin A1, a vacuolar-type H+-ATPase (H+-dependent adenosine triphosphatase) 
inhibitor that prevents the maturation of autophagic vacuoles (42), reversed the decrease in 
LC3-II that occurred 24 hours after ADI-PEG20 treatment, suggesting that there was active 
autophagic flux (Fig. 2C). To confirm that ADI-PEG20 induced autophagic flux, we used a 
flow cytometry–based assay to show that GFP-LC3 intensity was significantly decreased at 
24 and 48 hours after treatment with ADI-PEG20 (Fig. 2D).
To determine the role of autophagy in inhibiting cell proliferation mediated by ADI-PEG20, 
we used short hairpin RNA (shRNA) to knock down ATG5 and BECLIN 1 (fig. S2B), two 
essential components of the autophagy machinery (34, 35). Knockdown of ATG5 or 
BECLIN 1 decreased the sensitivity of MDA-MB-231 cells to ADI-PEG20 (Fig. 2, E and 
F). The size of the annexin V–positive population of MDA-MB-231 cells expressing shRNA 
against ATG5 was not significantly altered by ADI-PEG20 treatment or arginine starvation 
(Fig. 2A and fig. S2A). In addition, phase-contrast microscopy revealed that ADI-PEG20 or 
arginine starvation altered the overall morphology of MDA-MB-231 cells, but not cells 
stably transfected with ATG5 shRNA at 24 or 48 hours after treatment (fig. S2, C and D). 
Last, although the combination of ADI-PEG20 with rapamycin [a mammalian target of 
rapamycin (mTOR) inhibitor], an autophagy inducer, did not increase ADI-PEG20–
mediated cell killing, addition of chloroquine, an autophagic flux inhibitor, decreased ADI-
PEG20–induced cell death (fig. S2E). Therefore, we propose that autophagy is required for 
recombinant ADI-PEG20 to suppress MDA-MB-231 cell proliferation.
ADI-PEG20 impairs mitochondrial bioenergetics
Autophagy is a catabolic process that delivers intracellular proteins or organelles 
sequestered in autophagosomes to lysosomes for recycling, thereby providing energy during 
metabolic stress (34, 35). We have shown that glutamine depletion or autophagy impairment 
decreases ATP (adenosine 5′-triphosphate) production (43). We then analyzed the difference 
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of ATP concentrations during the course of ADI-PEG20 treatment in MDA-MB-231 cells 
stably transfected with control or ATG5 shRNA. ATP concentrations began to decrease 24 
hours after ADI-PEG20 treatment and continued to decrease to less than 50% of vehicle-
treated control cells at 48 hours after treatment (Fig. 3A). Knocking down ATG5 appeared 
to slow the reduction of ATP 48 hours after ADI-PEG20 treatment in MDA-MB-231 cells 
(Fig. 3A). Because mitochondria produce ATP through oxidative phosphorylation, we next 
analyzed whether arginine starvation by ADI-PEG20 affected the oxygen consumption rate 
of living cells. Oxygen consumption was assayed in the presence of the mitochondrial 
inhibitor oligomycin or in the presence of the mitochondrial uncoupler FCCP [carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone] to assess maximal oxidative capacity. First, 
we showed that MDA-MB-231 cells were already at maximal respiratory capacity for ATP 
synthesis under basal conditions, because oxygen consumption rate did not increase in 
response to FCCP treatment (Fig. 3B). Knockdown of ATG5 markedly decreased 
mitochondria-dependent respiration in MDA-MB-231 cells (Fig. 3B), consistent with a 
previous observation made in mouse embryonic fibroblasts (MEFs) (43). In cells treated 
with ADI-PEG20, the oxygen consumption rate for ATP synthesis was decreased and 
further inhibited by the ATP synthase blocker oligomycin. Moreover, the subsequent 
addition of FCCP failed to stimulate maximal respiration and, instead, caused it to fall below 
basal respiration, indicating that there was little or no uncoupled maximal respiration and 
reserve capacity (Fig. 3B). In contrast, FCCP partially stimulated rotenone-sensitive 
respiratory capacity in ADI-PEG20–treated cells with ATG5 knockdown. Likewise, the 
oxygen consumption rate of MDA-MB-231 cells cultured under arginine-free condition was 
comparable to that of cells treated with ADI-PEG20 (fig. S3A), suggesting that the lack of 
arginine is mainly responsible for ADI-PEG20-caused mitochondrial dysfunction. Together, 
these results suggest that autophagy exacerbates the impaired mitochondrial functions 
triggered by ADI-PEG20 treatment or arginine starvation in MDA-MB-231 cells.
Increasing the extracellular concentration of arginine, but not that of glutamine, attenuated 
the reduction in cell proliferation induced by ADI-PEG20 (Fig. 3C and fig. S3B). Moreover, 
excess arginine also largely rescued the oxygen consumption rate in ADI-PEG20–treated 
cells in a dose-dependent manner, thus suggesting that arginine deprivation was the critical 
mechanism underlying the cytotoxic effects of ADI-PEG20 and ruling out potential off-
target effect by ADI-PEG20 (fig. S3C). To investigate the metabolic defects caused by ADI-
PEG20, we analyzed the mRNA abundance profiles of untreated, ADI-PEG20–treated, or 
ADI-PEG20–treated and arginine-supplemented cells on oligonucleotide microarray chips 
and validated the array data by qRT-PCR. The top candidates affected by ADI-PEG20 
included NDUFB5, NDUFA9, NDUFB6, NDUFA8, NDUFB3, NDUFS3, and NDUFB1 
from complex I; SDHA and SDHB from complex II; UQCRFS1 from complex III; COX5A 
from complex IV; and ATP5G1, ATP5G2, ATP5J2, and ATP5L from complex V (Fig. 3D). 
The heatmap analysis also confirmed that the decreased transcript abundance in ADI-
PEG20–treated cells was reversed by supplementation with extracellular arginine. Notably, 
the ASS1 message and ASS1 protein abundance were increased by ADI-PEG20 and reduced 
by arginine supplementation (Fig. 3D).
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During mitochondrial electron transfer to the ATP synthase, both complexes I and II are 
involved in shuttling electrons to complex III (44-48). We found that adding more succinate 
for the complex II reaction rescued the reduced proliferation of ADI-PEG20–treated MDA-
MB-231 cells in a concentration-dependent manner (Fig. 3E and fig. S3D). Succinate did 
not noticeably rescue proliferation in ATG5-knockdown MDA-MB-231 cells (Fig. 3E and 
fig. S3D). Furthermore, knockdown of ASS1 decreased both basal and uncoupled oxygen 
consumption rate in ADI-PEG20–treated T47D cells (Fig. 3F), indicating that ASS1 status 
affects vulnerability of mitochondrial bioenergetics to ADI-PEG20. Together, these results 
suggest that the combination of loss of ASS1 and ADI-PEG20 treatment severely dampens 
mitochondrial respiratory function.
ADI-PEG20 increases ROS and decreases mitochondrial membrane potential in ASS1-
deficient MDA-MB-231 cells
There is a complex relationship between oxidative phosphorylation, electron transport, and 
the production of superoxide by mitochondria. Physiological uncoupling of ATP production 
from electron transport decreases superoxide production, whereas inhibiting the electron 
transport chain increases superoxide production (49). Furthermore, simultaneously 
uncoupling and inhibiting electron transport increases superoxide production (50). We used 
the oxidation of DCFDH to DCF (51) as a first approach (because of the limitations of 
fluorescent dyes in measuring specific reactive species) to determine whether ADI-PEG20 
increases the intracellular concentration of ROS that impairs mitochondrial respiratory 
function. Although the relative DCF signal in control MDA-MB-231 cells was lower than 
that in cells with ATG5 knockdown, ADI-PEG20 increased the relative signals of oxidized 
DCF in both sets of cells (Fig. 4A). The relative increase was greater in MDA-MB-231 cells 
(about threefold) than in MDA-MB-231 cells with ATG5 knockdown (less than twofold) 
(Fig. 4A). We used MitoSOX Red to further analyze the effect of ADI-PEG20 on 
nonmetabolic oxidation. ADI-PEG20 increased MitoSOX Red fluorescence ~12-fold in 
MDA-MB-231 cells, an increase that was significantly higher than the ~9-fold increase in 
the MDA-MB-231 cells with ATG5 knockdown (Fig. 4B). Consistently, mitochondrial 
membrane potential (MMP) was reduced by ADI-PEG20 to a greater extent in MDA-
MB-231 cells than in ATG5-knockdown MDA-MB-231 cells (Fig. 4C). Together, these 
observations suggest that autophagy competence exacerbated the mitochondrial damage 
induced by ADI-PEG20 in MDA-MB-231 cells (Figs. 3B and 4, A to C), supporting the 
hypothesis that ADI-PEG20–induced cell death is autophagy-dependent (Fig. 2, E and F).
The ADI-PEG20–induced increase in the generation of ROS (Fig. 4, A and B) could result 
from a decrease in the abundance of SIRT or superoxide dismutase (SOD) members. 
However, the mRNA abundance of SIRT and SOD family members showed no change in 
ADI-PEG20–treated or arginine-supplemented, ADI-PEG20–treated MDA-MB-231 cells 
(fig. S4, A and B). Thus, we used Western blotting to assess whether ADI-PEG20 treatment 
altered the abundance of mitochondrial proteins, including TOM20 (located in the 
mitochondrial outer membrane), COX IV (cytochrome c oxidase subunit IV; located in the 
mitochondrial inner membrane), cyclophilin D (located in the mitochondrial matrix), and 
SIRT3 [nicotinamide adenine dinucleotide (NAD)–dependent deacetylase sirtuin-3; located 
in the mitochondrial matrix], in control MDA-MB-231 cells and MDA-MB-231 cells with 
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ATG5 knockdown (Fig. 4D and fig. S4, C to F). The abundance of mitochondrial-specific 
SIRT3 was modestly decreased at an earlier time point of ADI-PEG20 treatment in MDA-
MB-231 cells (24 hours) than in the ATG5-knockdown MDA-MB-231 cells (48 hours) (Fig. 
4D and fig. S4F). Other mitochondria-specific proteins, including cyclophilin D, TOM20, 
and COX IV, showed decreased abundance over time in response to ADI-PEG20 in MDA-
MB-231 cells, supporting the involvement of mitochondrial dysfunction in response to ADI-
PEG20 (Fig. 4D and fig. S4, C to E). In contrast, an increase in the TOM20 and COX IV 
abundance at 24 hours after ADI-PEG20 treatment in cells with reduced ATG5 was noticed. 
Although it was reproducible, the underlying mechanism is unclear. Furthermore, adding the 
proteasome inhibitor MG132 mainly rescued the abundance of SIRT3 and cyclophilin D in 
ATG5-knockdown MDA-MB-231 cells. SIRT3 is located within mitochondria and is 
implicated in regulating metabolic processes through deacetylation of transcription factors 
or metabolic enzymes [reviewed in (52)]. Together with bioenergetics data (Fig. 3, A and 
B), these results showed that ADI-PEG20 treatment disrupted mitochondrial components in 
MDA-MB-231 cells. Finally, we demonstrated that modifying the abundance of SIRT3 (Fig. 
4E, inset) affected the sensitivity of cells to ADI-PEG20. SIRT3-overexpressing cells were 
more resistant to ADI-PEG20, whereas the knockdown of SIRT3 generally increased the 
cytotoxicity (Fig. 4E). Consistently, overexpression of SIRT3 decreased the basal 
concentration of ROS and attenuated its increase upon ADI-PEG20 treatment in MDA-
MB-231 cells (Fig. 4F). Last, knockdown of ASS1 increased the basal concentration of ROS 
and sensitized T47D cells to an ADI-PEG20–triggered increase in ROS production (Fig. 
4G).
ADI-PEG20 induces mitochondrial fragmentation in ASS1-deficient MDA-MB-231 cells
Our observation that autophagy-competent MDA-MB-231 cells were more likely to be 
subjected to ADI-PEG20–induced loss of mitochondrial function, such as decreased ATP 
production and oxygen consumption (Fig. 3, A and B), suggested an active role for 
autophagy in impairing mitochondrial function. Mitochondrial morphology is determined by 
the balance of fission and fusion (53), and using MitoTracker staining, we showed that 
mitochondrial syncytia were disrupted by ADI-PEG20 treatment in a time-dependent 
manner, suggestive of mitochondrial structural changes (fig. S5A). In MDA-MB-231 cells 
stably transfected with GFP-LC3, confocal microscopy revealed that GFP-LC3 and 
MitoTracker colocalized at 12 and 24 hours after ADI-PEG20 treatment, suggesting that 
mitochondria were being engulfed by autophagosomes (Fig. 5A). We then assessed how 
treatment of MDA-MB-231 cells with ADI-PEG20 affected the mitochondrial network. 
More than 50% of the cells before ADI-PEG20 treatment harbored vermiform mitochondria 
(fig. S5B). Exposure to ADI-PEG20 led to nearly all of the cells acquiring a fragmented 
mitochondrial structure (Fig. 5B). Next, cells cotreated with ADI-PEG20 and Mdivi1, an 
inhibitor of mitochondrial fission (54), showed a largely preserved filamentous 
mitochondrial morphology compared with cells treated with ADI-PEG20 alone (Fig.5B). 
Transmission electron microscopy (TEM) further revealed mitochondria that were engulfed 
in what were presumably autophagosomes in ADI-PEG20–treated MDA-MB-231 cells (fig. 
S5B). Moreover, TEM images also revealed swollen, fragmented mitochondria, which had 
lost their electron-dense staining (Fig. 5C). We propose that the swollen and decreased 
matrix density was caused by limited degradation and/or loss of the mitochondrial matrix 
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and cristae, the site of the mitochondrial respiratory chain, as well as degradation or loss of 
numerous carrier proteins (55). These data also insinuate a role for mitochondrial structural 
damage in ADI-PEG20–induced mitochondrial dysfunction. Lipid droplet number was 
increased (fig. S5B) and Oil Red O staining confirmed that more than 70% MDA-MB-231 
cells accumulated lipids 48 hours after ADI-PEG20 treatment (Fig. 5D). This increase 
provided additional, supporting evidence for the presence of damaged mitochondria, 
because mitochondria metabolize fatty acids through β-oxidation, and damage to 
mitochondria decreases the use of fatty acids, resulting in the accumulation of lipid droplets 
(56).
ASS1 abundance is a prognostic factor for overall breast cancer survival
We observed that ASS1 knockdown increased the ability of breast cancer cells to grow in an 
anchorage-independent manner (Fig. 1F and fig. S1E). To determine whether altered ASS1 
abundance affected overall survival (OS) of patients with breast cancer, we examined ASS1 
abundance in 149 breast cancer samples by staining three independent multiple tissue arrays 
with an anti-ASS1 antibody. We found that normal mammary tissues were ASS1-positive 
(Fig. 6A). However, 95 (63.8%) of the 149 breast cancer samples had low ASS1 abundance, 
which was defined as having little or no diffuse cytoplasmic ASS1 staining (Fig. 6A). In 
contrast, the remaining 54 breast cancer samples (36.2%) had high ASS1 abundance because 
they had strong diffuse staining in the cytoplasm (Fig. 6A). Our analyses of the clinical 
characteristics and pathology of the tumors revealed that reduced ASS1 abundance was 
significantly associated with advanced tumor stage and with progesterone receptor (PR)– 
and Ki-67–positive breast cancers (Table 1). However, there was no significant association 
with lymph node metastasis, or estrogen receptor (ER), HER2, or p53 status (Table 1). Last, 
the frequency of low ASS1 abundance was significantly different among all of the four 
different molecular breast cancer subtypes (Table 1).
Kaplan-Meier analyses indicated that reduced ASS1 abundance was a critical prognostic 
indicator for both OS (Fig. 6B) and DFS (disease-free survival) (Fig. 6C) for all 149 patients 
with breast cancer. Multivariate Cox analyses for OS rate indicated that patients with tumors 
with high ASS1 abundance had a lower relative risk of breast cancer–specific mortality 
[hazard ratio (HR), 0.21; 95% confidence interval, 0.03 to 0.73] (fig. S6A). Multivariate 
analysis also showed that high ASS1 abundance was associated with a lower relative risk of 
breast cancer relapse (HR, 0.44; 95% confidence interval, 0.14 to 1.20) (fig. S6B). 
Stratification analyses revealed that reduced ASS1 abundance was significantly associated 
with poor OS in the subgroups of patients with breast cancer who had ER-negative, PR-
negative, and Ki-67–positive cancers (fig. S6, C to E). The HR for high ASS1 abundance 
could not be calculated in ER-negative and HER2-positive breast cancers because no deaths 
were reported within these two subgroups during the follow-up period (fig. S6, C and G). In 
comparison with reduced ASS1 abundance, the adjusted HRs of high ASS1 abundance were 
0.16 (95% confidence interval, 0.01 to 0.98) and 0.23 (95% confidence interval, 0.04 to 
0.88) in the subgroups of PR-negative and Ki-67–positive breast cancers, respectively (fig. 
S6, D and E). Uni- and multivariate analyses indicated that reduced ASS1 abundance poorly 
impacted survival in both HER2-negative and HER2-positive subgroups (fig. S6, F and G), 
indicating that the loss of ASS1 abundance was associated with poor overall patient survival 
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independently of breast cancer molecular subgroup. Moreover, microarray analysis and 
associated clinical data extracted from a published study of 295 breast cancers revealed that 
ASS1 mRNA abundance from breast cancer samples of patients with >5-year OS or DFS 
was significantly higher than that in patients with <5-year OS or DFS (fig. S6H) (57, 58). 
Therefore, the abundance of ASS1 may be a useful biomarker for breast cancer prognosis 
and is consistent with the results of soft agarose growth assays, which indicated increased 
ability of cells with low ASS1 abundance to grow under anchorage-independent conditions 
(Fig. 1F and fig. S1E).
Autophagy is required for ADI-PEG20 to cause shrink tumors in vivo
For proof of principle, we determined the effects of autophagy competence and treatment 
with ADI-PEG20 on tumors in vivo. Female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice with 
xenografts formed from control MDA-MB-231 cells or MDA-MB-231 cells with ATG5 
knockdown were injected intravenously with vehicle control or ADI-PEG20. The tumors 
from ADI-PEG20–treated mice were smaller than tumors from control mice (Fig. 6D) at 19 
days after beginning treatment. Although ATG5 deficiency did not impair MDA-MB-231 
tumor growth, it markedly impaired shrinking of the tumors in response to ADI-PEG20 (Fig. 
6D). The average weight of ADI-PEG20–treated MDA-MB-231 tumors was significantly 
(50%) less than that of ADI-PEG20–treated MDA-MB-231/sh-ATG5 tumors (Fig. 6E). The 
data showing that MDA-MB-231 cells with ATG5 knockdown were more resistant to ADI-
PEG20 in vivo than control MDA-MB-231 cells support our conclusion that tumor 
shrinkage induced by ADI-PEG20 is autophagy-dependent.
Last, we examined if there was a synergistic effect between ADI-PEG20 and doxorubicin, 
cisplatin, or taxol, which are conventionally used as therapeutic agents against breast cancer, 
in MDA-MB-231 cells. The combination index (CI) of ADI-PEG20 with doxorubicin was 
assessed as previously described (59-61). CI < 1, CI = 1, and CI > 1 indicate synergism, 
additive effect, and antagonism, respectively (60, 61). The calculated CI suggested a 
synergistic effect between ADI-PEG20 and doxorubicin (Fig. 6F). However, synergy was 
not observed when ADI-PEG20 was combined with Abraxane or carboplatin (fig. S7). In 
summary, ADI-PEG20, alone or combined with doxorubicin, may represent a promising 
therapeutic strategy for treating breast cancers that are arginine auxotrophs.
DISCUSSION
Understanding the metabolic differences between normal cells and tumor cells could provide 
the opportunity to design selective personalized therapy against breast cancer and other 
cancers. Considerable attention has been paid to glucose metabolism and glutamine 
addiction in tumor cells (5). However, the metabolism of cancer cells is complex and 
involves various rewiring of metabolic pathways that occurs during malignant 
transformation. In this regard, we report here a mechanism connecting the metabolic stress 
caused by arginine starvation to induce cell death of ASS1-deficient breast cancer cells (Fig. 
6G). This is particularly interesting because arginine deprivation affected mitochondrial 
bioenergetics and integrity by decreasing the abundance of the mitochondrial inner 
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membrane and matrix proteins and impairing mitochondrial oxidative phosphorylation and 
ATP production, which was accompanied by increased ROS production.
The molecular mechanisms underlying cell death induced by ADI-PEG20–mediated 
arginine starvation of ASS1-deficient cells are not yet fully understood. Nutrient starvation, 
including arginine deprivation, often leads to autophagosome induction (19, 23, 37). 
Paradoxically, although other reports have suggested that autophagy protects cells from 
dying upon the initiation of starvation, our results showed that prolonged autophagy 
induction by sustained ADI-PEG20 treatment or arginine starvation eventually leads to cell 
death. To decipher this paradox, we examined the function and fate of mitochondria in ADI-
PEG20–treated MDA-MB-231 cells because mitochondria play a central role in satisfying 
higher demands for energy and anabolic needs during stress. Stressed cells have developed 
mechanisms, known as mitochondrial quality control, to deal with dysfunctional 
mitochondria to maintain homeostasis. Fusion between damaged mitochondria and healthy 
mitochondria may serve as one mechanism, either to dilute the damaged and detrimental 
components or to regain functional counterparts (62-64). Alternatively, sustained starvation 
induces the degradation of mitochondria by an autophagy-mediated system, known as 
mitophagy (65). Specifically, when damaged mitochondria lose their membrane potential 
(Fig. 4C) and/or undergo fragmentation (Fig. 5B), they are likely engulfed by 
autophagosomes for lysosomal degradation (65, 66). Our results suggest that the 
dysfunctional mitochondria, probably due to increased mitochondrial ROS production and 
the loss of MMP caused by disruptions in the respiratory chain (Figs. 3 and 4), resulted in 
cytotoxic autophagy in ADI-PEG20–treated MDA-MB-231 cells. This possibility is 
supported by studies in other systems in which mitophagy is triggered by the use of 
mitochondrial respiratory chain uncouplers (67-69).
We found that ADI-PEG20 decreased the steady-state abundance of complex I/II transcripts 
(Fig. 3D). It is possible that increased ROS production, presumably resulting from impaired 
mitochondrial function, may play a key role in favoring ADI-PEG20–induced cell death. 
Along the same lines, supplementing with succinate, a complex II substrate, partially 
rescued the viability of arginine-starved cells (Fig. 3E) by restoring portions of electron 
transfer capacity. Most likely, arginine starvation of cells lacking ASS1 affects 
mitochondrial integrity. We envision that ADI-PEG20 treatment in the context of ASS1 
deficiency creates a pathological “vicious cycle,” wherein the impairment in the 
mitochondrial electron transport that leads to a loss of MMP is also responsible for an 
incomplete O2 reduction, resulting in an increase in ROS production that further amplifies 
the generation of ROS. Consequently, sustained and excessive autophagy exacerbates the 
arginine starvation–induced cytotoxic effect (Fig. 6G). The consequence of sustained 
autophagy is reinforced by reduced biogenesis of new mitochondria caused by decreased 
amounts of complex I/II, which further inhibits oxidative phosphorylation and induces cell 
death. In support of this, Vincow et al. have shown that in the fly, several respiratory 
complex I proteins are selectively routed for autophagosomal degradation (70). Moreover, 
our data suggest that impairing or losing the mitochondrial electron transport chain could 
account for the lack of mitochondrial FCCP response after ADI-PEG20 treatment in cells 
with reduced ASS1 (Fig. 3F).
Qiu et al. Page 11
Sci Signal. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The reduction in SIRT3 protein abundance by prolonged ADI-PEG20 treatment (Fig. 4D) is 
of particular interest because SIRT3, which is located in the mitochondrial matrix, is a 
member of an evolutionarily conserved family of NAD+-dependent deacetylases that 
regulates lysine acetylation of mitochondrial proteins (52). Rardin et al. have shown that an 
absence of SIRT3 in the livers of fasted mice leads to selective hyperacetylation at 283 sites 
that represent 136 of the 483 acetylated mitochondrial proteins (71). One of the largest fold 
changes in lysine acetylation was observed for ATP synthase, a key enzyme involved in 
oxidative phosphorylation. In addition, these authors reported several SIRT3-regulated sites 
in complexes I, II, and IV. Lysine acetylation of mitochondrial proteins has been proposed 
to reduce complex I activity and decrease the basal ATP concentration (72). Besides 
oxidative phosphorylation, the SIRT3-regulated metabolic pathways in mitochondria also 
include fatty acid oxidation, tricarboxylic acid cycle, and branched chain amino acid 
catabolism (71). Conceivably, the decrease in SIRT3 abundance, albeit modest (Fig. 4D), 
could exacerbate the overall metabolic stress upon prolonged ADI-PEG20 treatment. This 
hypothesis is supported by the fact that overexpressing SIRT3 can rescue the viability of 
cells treated with ADI-PEG20 (Fig. 4E) by suppressing ROS concentrations (Fig. 4F).
ASS1 catalyzes a rate-limiting step in de novo arginine biosynthesis to maintain arginine 
serum concentrations. Our analyses indicate that ASS1 abundance is an independent 
prognostic indicator of the survival of patients with breast cancer (Fig. 6, B and C). We 
confirmed the potential role of ASS1 in inhibiting cells from growing in an anchorage-
independent manner (Fig. 1F and fig. S1E). A putative tumor suppressor role for ASS1 has 
been demonstrated by two independent studies (73, 74), although neither of these studies 
specifically examined breast cancer cells. Malignant transformation can be caused by or lead 
to metabolic changes because tumor cells tend to increase their glycolytic activity without a 
matching increase of oxidative phosphorylation and dependence on oxygen (a phenomenon 
known as the Warburg effect) (75, 76). The key to this metabolic rewiring is the decrease of 
mitochondrial respiration (77), which allows the cancer cells to grow in hypoxic conditions 
usually found in the interior of the tumor mass (78). However, the molecular mechanisms 
that suppress oxidative phosphorylation during tumorigenesis are still unclear. On the basis 
of our findings from the present work, we speculate that the down-modulating ASS1 
abundance leads to decreased oxidative phosphorylation (namely, decreased maximal 
respiratory capacity), potentially promoting neoplastic transformation. Indeed, we find that 
ASS1 behaves like a tumor suppressor because (i) ASS1 knockdown increased the 
anchorage-independent proliferation of breast cancer cells in vitro, and (ii) ASS1 deficiency 
or low ASS1 abundance is associated with a poor prognosis for patients with breast cancers. 
We further speculate that decreasing ASS1 abundance could create a prooxidant state (Fig. 
4G) that favors tumorigenesis because even a moderate increase in ROS production can 
promote cell proliferation and tumorigenesis (79). However, reduced ASS1 abundance also 
makes the breast cancer cells vulnerable to ADI-PEG20, which effectively kills them by 
starving them of arginine. This is reminiscent of the synthetic lethal interaction between 
BRCA1/2 deficiency and PARP1 inhibitors (80, 81).
In summary, we focused on how to take advantage of the mitochondrial dysfunction that is 
induced by sustained treatment of ADI-PEG20 in ASS1-deficient breast cancers. Our 
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observations have important implications for the development of tumor therapies because 
conventional thoughts suggest that activating autophagy may contribute to the survival, 
rendering, and recurrence of refractory tumors that are resistant to conventional 
chemotherapy. The synergistic effect observed between doxorubicin and ADI-PEG20 
supports the possibility of exploiting arginine starvation as a therapeutic strategy by 
targeting a specific metabolic liability due to ASS1 deficiency in breast cancer cells. The 
number of breast cancers and other human malignancies that have substantial subtypes that 
lack ASS1 abundance provides opportunities to validate our findings of a “mitochondria-
targeting mechanism” in human patients with ASS1-deficient breast cancers and other types 
of ASS1-deficient cancers.
MATERIALS AND METHODS
Patient enrollment, follow-up, and tissue array
Patients included in this study were diagnosed with breast cancer and treated by surgical 
resection between January 2002 and January 2006 in the Second Affiliated Hospital of 
Zhejiang University (ZJU). This study was approved by the Institutional Review Board 
(IRB) of the Second Affiliated Hospital of ZJU (IRB 210-025). A breast cancer pathologist 
(J.X.) used hematoxylin and eosin (H&E)–stained slides to retrospectively review the 
history of all cases. The clinicopathological parameters that were evaluated included patient 
age at the time of diagnosis, tumor node metastasis stage, date of last follow-up, and overall 
patient survival. Exclusion criteria were lack of a pathologic diagnosis, presence of multiple 
cancers, or loss of contact after surgery. A total of 149 patients with breast cancer met the 
inclusion criteria. All participants were periodically followed up, and surgery relapse and 
death data were collected until 2010. OS rate was calculated from the date of surgery to the 
date of death by breast cancer–associated illness. DFS rate was calculated from date of 
surgery to date of local recurrence or metastasis. If no death or relapse occurred, the OS and 
DFS rates were calculated from date of surgery to September 2010. The formalin-fixed, 
paraffin-embedded breast cancer tissue samples that were collected were reassembled into 
multiple tissue arrays. ASS1 immunohistological signals did not correlate with storage time 
(likelihood, P = 0.246), indicating that it was unlikely that storage time would affect the 
immunohistochemical outcome.
Immunohistochemistry
ASS1 protein abundance in the 149 breast cancer samples was assessed by 
immunohistochemistry (IHC) using an anti-ASS1 antibody (1:75 dilution) as previously 
described (82). The IHC conditions for ASS1 abundance determination were preoptimized 
on checkerboards with multiple tissue samples. Briefly, after deparaffinization, endogenous 
peroxidase activity was blocked by pretreatment with 3% H2O2. The slides were incubated 
with normal goat serum for 20 min at room temperature (RT) to block non-specific signal, 
then incubated with the primary antibody for 20 min at RT. The array slides were then 
incubated with polymer horseradish peroxidase (HRP)–labeled secondary antibodies for 30 
min at RT, and then 3,3′-diaminobenzidine (DAB)–treated [0.05 g of DAB and 100 ml of 
30% H2O2 in 100 ml of phosphate-buffered saline (PBS)] for 5 and 10 min, respectively. 
Each slide was counterstained with Dako’s hematoxylin. For each IHC staining, the negative 
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and positive checkerboards served as quality control. The specificity of anti-ASS1 antibody 
was validated by Western blotting. ASS1 staining was predominantly cytoplasmic, and 
ASS1 abundance was assessed using a visual grading system on the basis of the intensity of 
staining signals observed using a light microscope. Each sample was independently scored 
by two investigators (F.Q. and J.X.), including one breast pathologist (J.X.), using a double-
blind design to avoid scoring bias. Discrepancies were reevaluated by joint review between 
the two readers. ASS1-high was defined as strong diffusive staining, and ASS1-low was 
defined as weak diffusive staining or no staining (Fig. 6A).
Cell lines, media, and chemicals
Human embryonic kidney (HEK) 293T/FT, MDA-MB-231, ATG5-, BECLIN 1-, or SIRT3-
knockdown MDA-MB-231, ASS1, SIRT3 or GFP-LC3 stably transfected MDA-MB-231, 
MCF-7, ASS1-knockdown MCF-7, ZR-75-1, and MCF-10A cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro, 10-013-CV) containing fetal 
bovine serum (10%; Gibco, 26140), penicillin (100 U/ml), and streptomycin (100 μg/ml) 
(Gibco, 15240) at 37°C and 5% CO2 in a humidified incubator. T47D and ASS1-
knockdown T47D cells were cultured in RPMI 1640 medium under similar conditions. 
Recombinant ADI-PEG20 was a gift of Polaris Pharmaceuticals Inc. Bafilomycin A1 
(B1793), chloroquine diphosphate salt (C6628), rapamycin (R8781), succinic acid (S9512), 
L-arginine (A8094), and MG132 (M7449) were from Sigma. L-Glutamine solution was from 
Gibco (25030).
Antibodies
Anti–MAP1LC3-I/II antibody (M115-3) was from Medical & Biological Laboratories, anti-
SIRT3 antibody (C73E3) was from Cell Signaling Technology, anti-Tom20 antibody 
(sc-17764) and anti-GAPDH antibody (sc-25778) were from Santa Cruz Biotechnology, 
anti–cyclophilin D antibody (ab110324) and anti–COX IV antibody (ab110261) were from 
Abcam, and anti-actin antibody (MAB1501R) was from Millipore. Anti-human ASS1 
antibody and the lentiviral sh-ASS1 construct were from L.-J. Shen (83).
Virus production and transduction
Target gene DNA in a lentiviral backbone (pLKO.puro or pSin) (21 μg), pΔ8.7 (14 μg), and 
pVSV-G (7 μg) were transfected using Lipofectamine 2000 (Life Technologies, 11668-019) 
into HEK293T/FT cells that had been seeded in a T-175 flask and had reached 60% 
confluence on the day of transfection. On the second day after transfection, cells were 
treated with sodium butyrate (10 mM) to stimulate virus production. Media containing 
viruses were harvested on the fifth day and filtered through a 0.45-μm filter. For viral 
transduction, cells were treated with media containing viruses overnight in the presence of 
polybrene (8.3 μg/ml), which was followed by selection with puromycin (1 μg/ml) or G418 
(200 μg/ml), or analysis by fluorescence-activated cell sorting (FACS).
RNA extraction, qRT-PCR, and complementary DNA microarray analyses
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen, 74104) following the 
manufacturer’s instructions. The RNA concentration and purity were determined by 
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spectrophotometry (NanoDrop Technologies Inc., LLC). One microgram of total RNA was 
used as the template for synthesizing complementary DNA (cDNA) using the iScript cDNA 
Synthesis Kit (Bio-Rad, 170-8893). Real-time quantitative PCR was performed with the 
Single-Color Real-Time PCR Detection System (Bio-Rad). Equal amounts of mRNA from 
MDA-MB-231 cells subjected to a combination of ADI-PEG20 (0.3 μg/ml) and arginine 
(420 μg/ml) were analyzed. The relative abundance of ASS1 mRNA in each sample was 
compared to that of untreated MDA-MB-231 cells, which was designated as 1. For cDNA 
microarray analyses, the Illumina TotalPrep RNA Amplification Kit (Ambion) was used to 
transcribe 500 ng of RNA by following the manufacturer’s protocol. HumanHT-12 
Expression BeadChips (Illumina) used the Direct Hybridization Assay and were scanned on 
the BeadArray Reader to quantify signal and background intensity for each feature. The 
selected array data were validated by real-time PCR. All primer pair sequences are listed in 
table S1.
Cytotoxicity and apoptosis assays
Four methods were used to measure cytotoxicity. (i) In the DIMSCAN assay, 2500 to 5000 
cells were seeded onto 96-well plates. At the end of the indicated time periods of ADI-
PEG20 treatment, cells were incubated with fluorescein diacetate (40 μg/ml), which 
selectively accumulates in viable cells. A semiautomatic, fluorescence-based, digital image 
microscopy system was used to measure the viability. (ii) Real-time cell growth was 
monitored by using a 16× E-Plates RTCA DP Analyzer (ACEA Biosciences). (iii) Acid 
phosphatase (ACP) assays were used to avoid the effect of mitochondria dysfunction. 
Between 2500 and 5000 cells were seeded onto 96-well plates. At the end of the indicated 
time periods of ADI-PEG20 treatment, cells were washed twice with PBS and then 
incubated at 37°C for 30 min with 100 μl of pNPP (p-nitrophenol phosphate) solution (5 
mM) in a buffer containing sodium acetate (0.1 M) and Triton X-100 [0.1% (v/v), pH 5.5]. 
The reaction was terminated by adding NaOH (1 N, 10 μl), and the absorbance was 
measured at 410 nm using a microplate reader. (iv) Trypan blue exclusion was used to count 
viable cells under a light microscope. Relative cell viability of ADI-PEG20–treated cells 
was calculated relative to the respective viability of the corresponding matched, vehicle-
treated cells, which was designated as 1. Data were collected from at least three independent 
experiments and are shown as means ± SD. The interaction between drug combinations was 
analyzed using the CalcuSyn software program (Biosoft) to determine whether the 
combination was antagonistic, additive, or synergistic. This program is based on the Chou-
Talalay method to calculate a CI, and CI values less than 0.9 indicate synergistic effect. The 
CIs were determined from cell viability DIMSCAN or ACP assays as the fraction of cells 
killed by individual drugs, or combination of drugs, by comparing to vehicle-treated cells. 
For the apoptosis assay, cells were treated with ADI-PEG20 (0.3 μg/ml) or subjected to 
arginine starvation for the indicated time periods. After trypsinization, cells were washed 
twice with cold PBS and collected by centrifugation at 1000 rpm. Cells were then 
resuspended in 1× binding buffer at a concentration of 1 × 106 cells/ml, and 100 μl of the 
suspension (1 × 105 cells) was transferred to a polystyrene round-bottom tube. Cells were 
then stained with FITC (fluorescein isothiocyanate)–conjugated annexin V (4 μl) and 
propidium iodide (50 μg/ml, 5 μl). The mixture was gently vortexed and incubated for 15 
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min at RT, and 1× binding buffer (400 μl) was added to each tube before analyzing by flow 
cytometry.
Soft agar colony assays
Cells (0.5 × 104 to 3 × 104) were mixed in 0.35% agarose/complete medium and plated on a 
0.7% agarose/complete medium bottom layer in each well of a six-well plate. The culture 
medium contained vehicle or different concentrations of ADI-PEG20 and was changed 
every 2 to 3 days during the 4- to 6-week cell growth period. Colonies were stained with 
methylthiazolyldiphenyl-tetrazolium bromide (MTT; 0.2 mg/ml; Sigma, M5655) and were 
counted using a colony-counting software (VersaDoc Imaging System, Bio-Rad) or counted 
manually. Each experiment was performed at least twice in triplicate wells.
Whole-cell extracts and immunoblotting
Cells treated with ADI-PEG20 were harvested at the end of the incubation period and lysed 
on ice for 30 min in radioimmunoprecipitation assay buffer (Cell Signaling Technology, 
#9806) containing complete protease inhibitor cocktail (Roche, 11836145001) and 
PhosSTOP (Roche, 04906837001). The protein concentrations of whole-cell extracts were 
determined using a Bio-Rad Protein Assay Kit (500-0001). About 20 to 40 μg of protein 
were mixed with an equal volume of 2× SDS loading buffer, boiled for 5 min, and then 
separated by tris-glycine SDS–polyacrylamide gel electrophoresis and transferred to 
polyvinylidene difluoride membranes. The membranes were blocked with 5% nonfat milk in 
PBST (PBS containing 0.05% Tween 20) and incubated with primary antibodies at 4°C 
overnight. The membranes were then washed three times with PBST for 10 min and then 
incubated with HRP-labeled secondary antibodies for 2 hours at RT. Immunoblots were 
visualized using VersaDoc 5000 Imaging System (Bio-Rad). The intensity was determined 
using Quantity One (Bio-Rad) and compared to 0-hour treatment after normalizing with 
actin. Three independent experiments were performed, and representative blots were 
presented.
ATP assay
The ENLITEN ATPAssay System (Promega, FF2000) was used according to the 
manufacturer’s instructions. At the indicated time points, cells were harvested by scraping 
and resuspending in PBS (500 μl). The cell suspension was divided into unequal aliquots, 
and 400 μl of cell suspension was mixed with 5% trichloroacetic acid (TCA; 100 μl). The 
remaining cells (100 μl) were used for cell number calculation. Tris-acetate buffer (900 μl, 
pH 7.75) was then added to neutralize the TCA and to dilute the TCA to a final 
concentration of 0.1%. The extracts were further diluted 100-fold with dilution buffer (0.1% 
TCA, 0.08× PBS, and 0.9× tris-acetate). Diluted sample (40 μl) was added to an equal 
volume of rL/L Reagent (Promega, FF2000) that contained D-luciferin and recombinant 
luciferase, and then luminescence was measured using a TD-30e luminometer (Turner). The 
ATP standard (Promega, FF2000) was serially diluted to generate a regression curve for 
calculating ATP concentrations in individual samples. The relative ATP concentration was 
determined and normalized to that of vehicle-treated cells, which was designated as 1. Three 
independent experiments were performed, and results are presented as means ± SD.
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Oxygen consumption rate
Cellular mitochondrial function was measured using the Seahorse Bioscience XF24 
Extracellular Flux Analyzer. The mitochondrial function was assayed by sequential 
injections of oligomycin, FCCP, and rotenone to define basal oxygen consumption rate, 
ATP-linked oxygen consumption rate, proton leak, maximal respiratory capacity, reserve 
respiratory capacity, and nonmitochondrial oxygen consumption, all according to the 
manufacturer’s instructions. Oligomycin A inhibits ATP synthase by blocking proton 
channel and reduces electron flow through the electron transport chain, which is necessary 
for oxidative phosphorylation of ADP (adenosine 5′-diphosphate) to ATP. FCCP is a 
protonophore (H+ ionophore) and uncoupler of oxidative phosphorylation in mitochondria, 
which is capable of depolarizing plasma and mitochondrial membranes. Rotenone, an 
inhibitor of mitochondrial electron transport at NADH (reduced form of NAD+)/ubiquinone 
oxidoreductase, inhibits the transfer of electrons from iron-sulfur centers in complex I to 
ubiquinone and interferes with NADH. Basal oxygen consumption rate was a proxy for 
mitochondria function. Briefly, 2 × 104 cells were seeded onto 24-well plates and incubated 
overnight before sequentially adding preoptimized concentrations of oligomycin, FCCP, and 
rotenone, in that order. After washing the cells with 1 ml of Seahorse buffer [DMEM 
without phenol red containing glucose (4.5 g/liter; Sigma, G7021), sodium pyruvate (1 mM; 
Gibco, 11360070), and glutamine (4 mM; Gibco, 25030081)], 600 μl of Seahorse buffer plus 
60 μl each of oligomycin (50 μg/ml; Sigma, 75351), FCCP (10 μM; Sigma, C2920), and 
rotenone (10 μM; Sigma, R8875) was automatically injected. At the end of the recording 
period, cells were collected and cell numbers were determined using a trypan blue exclusion 
assay. Oxygen consumption rate values were calculated after normalizing with the cell 
number and plotted as the means ± SD.
Fluorescence-based methods to measure DCFDH oxidation, MitoSOX Red oxidation, MMP, 
and autophagic flux
To measure DCFDH oxidation, cells were stained with DCFDA (10 μM; Sigma, D6883) for 
30 min before flow cytometry analysis (Gallios, Beckman Coulter). In a second fluorescent 
dye oxidation measurement, cells were incubated with MitoSOX Red (5 mM; Life 
Technologies, M36008) for 30 min in serum-free DMEM. We used increased oxidized DCF 
and MitoSOX Red fluorescence as indicators of increased nonmetabolic oxidation, which is 
consistent with oxidative stress, although we acknowledge that dye oxidation by itself does 
not actually represent the increased production of ROS (51). For MMP analyses, cells were 
incubated in DMEM with DiOC6 (10 nM; Sigma, 318426) for 30 min before analyses. For 
autophagic flux analyses, MDA-MB-231/GFP-LC3 cells were harvested after ADI-PEG20 
treatment for different time periods, and immediately analyzed by flow cytometry. Data 
were collected from three independent experiments and are presented in a histogram. The 
flow cytometry analyses were performed with FlowJo software (Tree Star).
Confocal microscopy and TEM
MDA-MB-231 cells stably transfected with GFP-LC3 cells were cultured in six-well plates 
with cover slips at a density of 1 × 105 cells per well, and then treated with ADI-PEG20 for 
0, 12, and 24 hours, respectively. Cells were stained with MitoTracker Deep Red FM (300 
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nM; Life Technologies, M22426) for 15 min in serum-free DMEM. After washing with 
PBS, the cover slips were mounted over a microscope slide in ProLong Gold Antifade 
Reagent that contained DAPI (4′,6-diamidino-2-phenylindole) (Life Technologies, 
P-36931), and examined using a Stallion Digital Imaging Station (Carl Zeiss Microscopy). 
For mitochondria morphology characterization, MDA-MB-231 cells were cultured in six-
well plates with cover slips at a density of 5 × 105 cells per well, and then treated with 
Mdivi1 (10 μM; Sigma, M0199), ADI-PEG20, or combination of both for 24 hours. Cells 
were stained with TOM20 for 1 hour at RT after fixation with 4% paraformaldehyde in PBS 
and permeabilized with 1% Triton X-100. After washing, secondary antibody conjugate with 
Alexa Fluor 488 was added and incubated for 30 min at RT. Finally, slides were mounted 
using ProLong Gold Antifade Reagent and imaged using confocal microscopy as described 
above. For TEM studies, cell pellets were fixed in glutaraldehyde {2% in 0.1 M cacodylate 
buffer [Na(CH3)2AsO2·3H2O], pH 7.2} at 4°C overnight. The cell pellets were then washed 
three times with 0.1 M cacodylate buffer (pH 7.2), postfixed with OsO4 (1% in 0.1 M 
cacodylate buffer) for 30 min, and then washed three times again with cacodylate buffer (0.1 
M). The samples were dehydrated using a series of 60, 70, 80, and 95% ethanol, and then 
100% absolute ethanol (twice) and propylene oxide (twice), and were then placed in 
propylene oxide/Eponate (1:1) overnight at RT. The vials were sealed for overnight 
incubation, and then opened the next day for 2 to 3 hours to allow the propylene oxide to 
evaporate. Finally, the samples were infused with 100% Eponate and polymerized at −64°C 
for 48 hours. Ultrathin sections (~70 nm thick) were prepared using a Leica Ultracut UCT 
Ultramicrotome with a diamond knife, picked up on 200-mesh copper electron microscopy 
grids. Grids were stained with uranyl acetate (2%) for 10 min, followed by Reynold’s lead 
citrate staining for 1 min. The samples were viewed using a FEI Tecnai 12 TEM equipped 
with a Gatan UltraScan 2k CCD (charge-coupled device) camera. Three independent 
experiments were performed, and representative images are shown.
Oil Red O staining
MDA-MB-231 cells were cultured in six-well plates with cover slips at a density of 5 × 105 
cells per well, and then treated with ADI-PEG20 for 0, 24, and 48 hours, respectively. Cells 
were fixed using 4% paraformaldehyde in PBS for 30 min. Each well was gently rinsed 
twice with 1 ml of deionized water. Sixty percent isopropanol (1.5 ml) was added to each 
well for 5 min. Isopropanol was then removed and replaced with 1.5 ml of Oil Red O 
working solution (2 mg/ml in 60% isopropanol; Sigma, O0625) for 10 min at RT. Each well 
was rinsed with tap water until clear and counterstained with hematoxylin for 1 min. Last, 
each well was rinsed with tap water and mounted with 70% glycerol.
Xenograft studies
MDA-MB-231 (5 × 106) and ATG5-knockdown MDA-MB-231 cells (resuspended in 100 μl 
of serum-free DMEM) were injected subcutaneously into the right flank of 6-week-old 
female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (NOD-SCID) mice. Mice were randomized 
at day 10 after tumor inoculation and received either vehicle or 4 IU of ADI-PEG20 (0.2 ml) 
weekly through tail vein injection (intravenous) for 3 weeks (n = 5 mice per group). Tumor 
volume was measured weekly. Mice were euthanized on day 35, 4 days after the last 
injection. Tumors were harvested for weight measurement and H&E staining. Animal 
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experiments were approved by the Institutional Animal Care and Use Committee at City of 
Hope.
Statistical analysis
The database was created using Microsoft Excel and analyzed using JMP 8.0 (SAS Institute) 
and GraphPad Prism 5.0 software programs. Group comparisons for normal distribution data 
were done by t test (two samples) and one-way analysis of variance (ANOVA) (multiple 
comparisons). The nonparametric Wilcoxon test was used for continuous nonnormal 
distribution data. For multiple comparisons, Tukey-Kramer HSD (honestly significant 
difference) and Steel-Dwass methods were applied for following pairs’ comparison in 
ANOVA and nonparametric Wilcoxon test, respectively. Categorical variables were 
compared using χ2 analysis, Fisher’s exact test, or binomial test of proportions. Kaplan-
Meier analysis and COX hazard proportional model were used to analyze OS and DFS. 
Multivariate analysis and stratification were used to reduce the confounder’s impact on the 
estimation of the HR. Statistical significance was set as P < 0.05, two-tailed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Arginine starvation inhibits cell proliferation of ASS1-deficient breast cancer cells
(A) ASS1 abundance varies in different breast cancer cell lines and immortalized MCF-10A 
cells. ASS1 mRNA abundance was analyzed by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR; upper panel), and ASS1 protein abundance was 
assessed by Western blotting (lower panel). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) message or GAPDH protein abundance was used to normalize qRT-PCR results 
or to assure equal loading; n = 3 sets of cells. (B) Inverse correlation between ASS1 protein 
abundance and the cytotoxic effects of ADI-PEG20 on four breast cancer cell lines; n = 4 
sets of cells. (C) Anchorage-independent growth of MDA-MB-231 cells is affected by ADI-
PEG20 treatment; n = 2 sets of cells in triplicates (total 6). (D) Overexpression of ASS1 
increases the IC50 (median inhibitory concentration) of ADI-PEG20 in MDA-MB-231 cells 
from 0.2 to 0.3 μg/ml; n = 3 sets of cells. (E) Knockdown of ASS1 abundance decreases 
IC50 of ADI-PEG20 in T47D cells (from greater than 0.4 to 0.075 μg/ml); n = 3 sets of cells. 
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(F) Knockdown of ASS1 abundance sensitizes MCF-7 cells to ADI-PEG20 in colony 
formation assays; n = 2 sets of cells in triplicates (total 6). (C and F) Representative images 
show total colony area or a selected area of colony growth (enlarged; insets) on day 28. Bar 
graph representing means ± SD from individual set of three technical repeats is shown on 
the right. Viability and qRT-PCR data are shown as means ± SD; *P < 0.05.
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Fig. 2. ADI-PEG20 induces autophagy-dependent cell death
(A) ADI-PEG20 treatment or arginine starvation moderately increases apoptotic cell 
percentage in MDA-MB-231 cells. Knockdown of ATG5 in MDA-MB-231 cells does not 
significantly affect response to ADI-PEG20 treatment or arginine starvation. Histograms are 
presented as means ± SD; n = 3 sets of cells. (B) Representative images of GFP-LC3 puncta 
formation (indicated by arrows) using fluorescence microscopy; n = 5 sets of cells. Scale 
bars, 50 mm. (C) ADI-PEG20 induces LC3 lipidation, which is reversed by bafilomycin A1. 
One representative Western and bar graph, presented as means ± SD, are shown; n = 3 sets 
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of cells. (D) ADI-PEG20 induces autophagic flux. MDA-MB-231 cells overexpressing 
GFP-LC3 were treated with ADI-PEG20 for the indicated time periods and analyzed by 
flow cytometry (left panel). Data are shown as means ± SD (right panel); n = 3 sets of cells. 
*P < 0.05. (E and F) Knockdown of ATG5 (E) or BECLIN 1 (F) reduces ADI-PEG20-
induced cytotoxicity. n = 3 sets of cells; *P < 0.05.
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Fig. 3. ADI-PEG20 impairs mitochondrial function
(A) Autophagy-dependent ATP concentration decreases over time in ADI-PEG20–treated 
MDA-MB-231 cells; n = 3 sets of cells; *P < 0.05. (B) Combination of ADI-PEG20 
treatment and ATG5 gene context regulates the basal and maximal mitochondrial respiration. 
ATG5 knockdown partially rescued the maximal respiration stimulated by FCCP in MDA-
MB-231 cells treated with ADI-PEG20; n = 3 sets of cells. OCR, oxygen consumption rate. 
(C) Extracellular arginine reverses the reduced cell proliferation induced by ADI-PEG20 in 
a dose-dependent manner; n = 5 sets of cells; *P < 0.05. (D) ADI-PEG20 treatment 
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reversibly decreases the abundance of mRNAs encoding mitochondrial respiratory chain 
proteins (left panel). A list of top candidates includes messages encoding proteins of 
complex I (blue) and complex II (orange). Other messages shown in black are UQCRFS1 
(complex III), COX5A (complex IV), and ATP5G1 and ATP5J2 (complex V). Arginine 
supplementation rescued ASS1 message and protein abundance in ADI-PEG20–treated 
MDA-MB- 231 cells (right panel), thus verifying the effectiveness of arginine 
supplementation. Bar graph, presented as means ± SD, from three independent Western 
blots is shown. ATP5L (complex V) message abundance increased in response to ADI-
PEG20, and then decreased after the addition of arginine. (E) Succinate rescues the 
cytotoxic effect of ADI-PEG20. Data are shown as means ± SD; n = 3 sets of cells; *P < 
0.05. (F) Knockdown of ASS1 suppresses basal and uncoupled mitochondrial OCR in T47D 
cells; n = 3 sets of cells.
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Fig. 4. ADI-PEG20 induces mitochondrial ROS
(A to C) ADI-PEG20 increases ROS. DCFDH oxidation (A), MitoSOX Red oxidation (B), 
and MMP as assessed by DiOC6 staining (C) were determined by flow cytometry. Data are 
shown as means ± SD; n = 3 sets of cells; *P < 0.05. (D) Representative Western blot shows 
that autophagy promotes ADI-PEG20–induced decrease of the mitochondrial protein 
cyclophilin D, TOM20, COX IV, and SIRT3 abundance in MDA-MB-231 cells; n = 3 sets 
of cells. Equal amounts of whole-cell lysates were analyzed by Western blot for the 
indicated mitochondrial proteins. One representative Western is shown, and quantitative 
analysis of densitometric tracing, presented as means ± SD, for cyclophilin D, TOM20, 
COX IV, and SIRT3 is shown in fig. S4 (C to F); n = 3 sets of cells. (E) SIRT3 abundance 
governs ADI-PEG20 sensitivity. SIRT3 abundance was modified by lentiviral 
overexpression (+SIRT3) or knockdown (sh-SIRT3). Data are shown as means ± SD; n = 3 
sets of cells; *P < 0.05. (F and G) Both SIRT3 and ASS1 are involved in regulating ROS 
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production in ADI-PEG20–treated breast cancer cells. DCFDH oxidation was determined by 
flow cytometry in MDA-MB-231, SIRT3-overexpressing MDA-MB-231 (F), T47D, and 
ASS1-knockdown T47D cells (G). The positively stained population in vehicle-treated 
parental cells was designated as 1 to calculate the relative extent of DCF oxidization. Data 
are shown as means ± SD; n = 5 sets of cells; *P < 0.05.
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Fig. 5. ADI-PEG20 causes mitochondrial fragmentation
(A) GFP-LC3 puncta colocalize with MitoTracker. The number of GFP-LC3 puncta was 
highest in cells treated with ADI-PEG20 for 12 hours, and then, they decreased after 24 
hours of treatment. Part of GFP-LC3 and MitoTracker signals are colocalized after ADI-
PEG20 treatment. Magnified images are shown in the upper right corner (Merge). n = 3 sets 
of cells. Scale bars, 5 μm. (B) Representative confocal images of MDA-MB-231 cells 
treated with a combination of ADI-PEG20 and Mdivi1 for 24 hours and stained with an anti-
TOM20 antibody (upper panel); n = 3 sets of cells. Mitochondria lengths were measured and 
scored as follows: fragmented (<2 μm; arrowheads), intermediate (2 to 3 μm; arrows), and 
filamentous (>3 μm; block arrows). The percentage of cells with indicated dominant 
mitochondrial morphologies was determined by dividing by the total number of counted 
cells as indicated (lower panel); scale bars, 20 μm. Magnified images are shown in the insets 
(upper left); scale bars, 10 μm. (C) Representative TEM micrographs showing damaged and 
swollen mitochondria after ADI-PEG20 treatment (indicated by arrows). Scale bars, 1 μm 
(upper panels) and 0.5 μm (lower panels). n = 3 sets of paired cells. (D) Representative 
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images of Oil Red O staining after treatment with ADI-PEG20 for indicated time periods; n 
= 4 sets of cells. The percentage of cells with the oil droplets was counted and determined as 
a percentage of the total number of examined cells. Scale bars, 10 μm; *P < 0.05.
Qiu et al. Page 37
Sci Signal. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 6. Low ASS1 abundance is prognostic of poor breast cancer survival and predisposes MDA-
MB-231 cells to ADI-PEG20–mediated tumor shrinkage in an autophagy-dependent manner in 
vivo
(A) Representative ASS1 immunohistochemical staining of 149 breast cancer samples. 
Normal breast epithelium (left panels), breast cancer tumors with low ASS1 abundance 
(middle panel; score: 0 and 1), and breast cancer tumors with high ASS1 abundance (right 
panels; score: 2 and 3). Scale bars, 100 μm. (B) Kaplan-Meier analysis indicates that 
reduced ASS1 abundance in breast tumors is significantly associated with poor OS. (C) 
Kaplan-Meier analysis shows low ASS1 abundance in breast tumors impacts DFS. The 
Qiu et al. Page 38
Sci Signal. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
sample number was reduced from 149 to 148 because a patient died before metastasis 
occurred. (D) Representative images of tumors harvested from either vehicle- or ADI-
PEG20–treated mice xenografted with MDA-MB-231 or ATG5-knockdown cells. 
Magnification, ×50; scale bars, 1000 μm. (E) Scatter plot of tumor weight measured at the 
endpoint of experiment. One dot represents one mouse with total of five mice per group, and 
“–” represents the average (145.4 ± 28.4, 176.6 ± 42.2, 92.4 ± 28, and 185.8 ± 18.9 mg; n = 
5; *P < 0.05). Statistical analysis showed a significant difference between vehicle- and ADI-
PEG20–treated MDA-MB-231 groups, and between ADI-PEG20-treated and ATG5-
knockdown MDA-MB-231 groups. (F) Synergistic effect of ADI-PEG20 combined with 
doxorubicin; n = 3 sets of cells. (G) Proposed model depicting ADI-PEG20–induced 
cytotoxic killing. The location of ADI-PEG20–induced alterations within mitochondrial and 
cell death pathways is indicated by the numbers inside blue crosses: respiration chain (1), 
membrane permeability (2), oxidative stress (3), and activation of excessive autophagy (4).
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Table 1
Clinicopathological characteristics and ASS1 distribution of eligible patients with breast 
cancer
No. of cases
No. of patients
with low ASS1
abundance (%)*
P
Age (years)
 <40 12 9 (75)
 40–49 53 34 (64.1)
 50–59 43 26 (60.5)
 60–69 23 15 (65.2)
 70–79 14 10 (81.4)
 >80 4 3 (75.0) 0.573
T stage†
 T0–T1 36 15 (41.7)
 T2–T4 108 76 (70.4) 0.002‡
N stage†
 N0 72 44 (61.1)
 N1–N3 77 51 (66.2) 0.516
ER
 Negative 52 30 (57.7)
 Positive 73 47 (64.4) 0.448
PR
 Negative 62 30 (48.4)
 Positive 60 43 (71.7) 0.009‡
Ki-67
 Negative 48 36 (75.0)
 Positive 78 51 (55.3) 0.012‡
HER2
 Negative 97 63 (64.9)
 Positive 30 14 (46.7) 0.07
Molecular subtype§
 Luminal A 36 27 (75)
 Luminal B 43 26 (60.5)
 TNBC 22 12 (54.5)
 HER2 12 2 (16.7) 0.005‡
p53
 Negative 62 42 (67.7)
 Positive 61 33 (54.1) 0.12
*
Either no staining or weak cytoplasmic ASS1 staining.
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†
Tumor node metastasis stage is according to AJCC Cancer Staging Manual, 6th Edition.
‡Statistical significance, P < 0.05.
§
Molecular subtype is categorized according to ER, PR, HER2, and Ki-67 status. Luminal A subtype is defined as ER-positive and/or PR-positive, 
HER2-negative, and Ki-67–negative; luminal B subtype is defined as ER-positive and/or PR-positive, HER2-negative, and Ki-67–positive; TNBC 
subtype is defined as ER-negative, PR-negative, and HER2-negative; HER2 subtype is defined as ER-negative, PR-negative, and HER2-positive.
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